VolitionRx Limited (VNRX)
Market Cap | 74.24M |
Revenue (ttm) | 1.32M |
Net Income (ttm) | -23.32M |
Shares Out | 107.60M |
EPS (ttm) | -0.25 |
PE Ratio | n/a |
Forward PE | n/a |
Dividend | n/a |
Ex-Dividend Date | n/a |
Volume | 104,344 |
Open | 0.6550 |
Previous Close | 0.6564 |
Day's Range | 0.6400 - 0.6900 |
52-Week Range | 0.3951 - 0.9400 |
Beta | 1.26 |
Analysts | Strong Buy |
Price Target | 3.50 (+407.25%) |
Earnings Date | Aug 14, 2025 |
About VNRX
VolitionRx Limited, a multi-national epigenetics company, develops blood tests to help detect and monitor a range of cancers, and diseases associated with NETosis in the United States, Europe, and Asia. The company offers Nu.Q Vet, a cancer screening test for dogs and other animals; Nu.Q Nets, detects diseases associated with NETosis, such as sepsis; Nu.Q Discover, a solution to profiling nucleosomes; Nu.Q Cancer for predicting treatment response, monitoring treatment response and disease progression, and amending a patient’s cancer treatment r... [Read more]
Financial Performance
In 2024, VolitionRx's revenue was $1.23 million, an increase of 59.10% compared to the previous year's $775,302. Losses were -$26.97 million, -23.65% less than in 2023.
Financial StatementsAnalyst Summary
According to 4 analysts, the average rating for VNRX stock is "Strong Buy." The 12-month stock price target is $3.5, which is an increase of 407.25% from the latest price.
News

VolitionRx Limited (VNRX) Q2 2025 Earnings Call Transcript
VolitionRx Limited (NYSE:VNRX) Q2 2025 Earnings Conference Call August 15, 2025 8:30 AM ET Company Participants Andrew Retter - Chief Medical Officer Cameron Reynolds - Founder, CEO, President & Dire...

VolitionRx Limited Announces Second Quarter 2025 Financial Results and Business Update
Conference call to discuss financial and operational results scheduled for Friday, August 15 at 8:30 a.m. U.S. Eastern Time HENDERSON, Nev.

VolitionRx Limited Schedules Second Quarter 2025 Earnings Conference Call and Business Update
Conference call to take place on Friday, August 15 at 8:30 a.m. U.S Eastern Time HENDERSON, Nev.

VolitionRx Announces Pricing of $1.2 Million Registered Direct Offering
HENDERSON, Nev. , Aug. 4, 2025 /PRNewswire/ -- VolitionRx Limited (NYSE American: VNRX) ("Volition" or the "Company"), a multi-national epigenetics company, announced today that it has entered into de...

Nu.Q® Discover Expands Global Adoption and Epigenetic Innovation
HENDERSON, Nev., July 16, 2025 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition"), a multi-national epigenetics company, today provides an update on the significant commercial and s...

Volition Announces Groundbreaking Lateral Flow Test for Point-of-Care Quantification of Nucleosomes
HENDERSON, Nev. , July 8, 2025 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition"), a multi-national epigenetics company, today announces it has demonstrated quantification of nucleo...

Volition Announces MARS Consortium Clinical Study Suggests Nu.Q® H3.1. Concentrations are Closely Associated with Sepsis and Organ Failure
Peer Reviewed Clinical Study for H3.1 Biomarker Published in Critical Care HENDERSON, Nev. , June 12, 2025 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition"), a multi-national epige...

Volition Announces Two Oral Presentations at Asian Meeting of Animal Medicine Specialties
HENDERSON, Nevada , June 4, 2025 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition"), a multi-national epigenetics company, today announces two oral presentations featuring its Nu.Q®...

VolitionRx Limited Announces Successful Detection of Nucleosomes in Cats
Clinical Paper Published in BMC Veterinary Research HENDERSON, Nev. , May 19, 2025 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition"), a multi-national epigenetics company, today an...

VolitionRX Limited (VNRX) Q1 2025 Earnings Call Transcript
VolitionRX Limited (NYSE:VNRX) Q1 2025 Earnings Conference Call May 16, 2025 8:30 AM ET Company Participants Louise Batchelor – Chief Marketing and Communications Officer Terig Hughes – Chief Financi...

VolitionRx Limited Announces First Quarter 2025 Financial Results and Business Update
Conference call to discuss financial and operational results scheduled for Friday, May 16 at 8:30 a.m. U.S. Eastern Time HENDERSON, Nev.

VolitionRx Limited Schedules First Quarter 2025 Earnings Conference Call and Business Update
Conference call to take place on Friday, May 16 at 8:30 a.m. U.S Eastern Time Henderson, Nev.

VolitionRX Limited: Outlines broad strategy to become the 'NETs company' worldwide through licensing and updates progress of Nu.Q® NETs test adoption
HENDERSON, Nev. , May 7, 2025 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition"), a multi-national epigenetics company, today announces that Chief Commercial Officer, Gael Forterre,...

VolitionRX Limited: Revolutionizing the diagnosis and monitoring of life-altering diseases for both humans and animals in multi-billion dollar markets
HENDERSON, Nev. , April 29, 2025 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition"), a multi-national epigenetics company, today announces that President and Group Chief Executive O...

VolitionRx Limited (VNRX) Q4 2024 Earnings Call Transcript
VolitionRx Limited (NYSE:VNRX) Q4 2024 Earnings Conference Call March 31, 2025 4:30 PM ET Company Participants Louise Batchelor - Chief Marketing & Communications Officer Cameron Reynolds - President...

VolitionRx Limited Announces Full Fiscal Year 2024 Financial Results and Business Update
Conference call to discuss financial and operational results scheduled for Monday, March 31 at 4:30 p.m. U.S. Eastern Time HENDERSON, Nevada , March 31, 2025 /PRNewswire/ -- VolitionRx Limited (NYSE A...

Volition Announces Two Poster Presentations at ESMO's European Lung Cancer Congress 2025
Studies demonstrate how Volition's Nu.Q®H3K27Me3 biomarker, when combined with ctDNA, may improve the prognostic value for overall survival and could help inform treatment decisions in NSCLC; and how ...

Volition to Host Virtual Investor Event on Nu.Q® Cancer, "A Look to the Future of Cancer Diagnostics", on April 9, 2025
HENDERSON, Nev. , March 27, 2025 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition"), a multi-national epigenetics company, today announces it will host a virtual investor event on W...

VolitionRx Announces Pricing of up to $2.3 Million Registered Direct Offering
Up to $2.3 million up front with up to an additional $1.1 million of potential aggregate gross proceeds upon the exercise in full of common stock purchase warrants HENDERSON, Nev. , March 26, 2025 /PR...

VolitionRx Limited Schedules Full Fiscal Year 2024 Earnings Conference Call and Business Update
Conference call to take place on Monday, March 31 at 4:30 p.m. U.S Eastern Time HENDERSON, Nev.

Volition's Nu.Q® Cancer Diagnostics Test Aims To Disrupt the Multi-Billion Dollar Liquid Biopsy Industry
Volition study shows rapid, low-cost, automated Nu.Q® Cancer test accurately detects human cancers at high specificity HENDERSON, Nev. , March 21, 2025 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICA...

Volition Introduces Nu.Q® Cancer Blood Test in New Industry Primer for Lung Cancer
"Lung Cancer: Hope of a Brighter Tomorrow" illustrates how Nu.Q® Cancer Test aims to transform the diagnosis, treatment and monitoring in the $4 billion lung cancer market1 HENDERSON, Nev. , March 20,...

Volition Proudly Sponsors the 44th ISICEM Congress
Volition to host multiple presentations at the International Symposium on Intensive Care & Emergency Medicine in Brussels, Belgium, from March 18 - 21 HENDERSON, Nev. , March 17, 2025 /PRNewswire/ --...

Volition Signs first ever Nu.Q® Vet Cancer Test Automation Agreement with Fujifilm Vet Systems
HENDERSON, Nev. , March 13, 2025 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition"), a multi-national epigenetics company, today announced the expansion of its Nu.Q® Vet Cancer Test...

Volition Announces First Patient Enrolled in NTU Hospital's Prospective Validation Study of Nu.Q® Lung Cancer Test
Published study shows Nu.Q® Lung Cancer Test differentiated malignant and benign nodules found by Low Dose CT screening. The study is expected to be completed by the end of 2025 HENDERSON, Nev.